J&J's amivantamab plus chemo hits 34-month OS in EGFR Ex20ins NSCLC

Final PAPILLON Phase 3 data show a 34.3-month median overall survival with amivantamab plus chemotherapy, the longest reported in this historically difficult-to

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit hospital room features an IV bag and pump mounted on a pole in the foreground, with a large window and a blurred hospital bed in the background.

Johnson & Johnson has reported final overall survival data from the Phase 3 PAPILLON study, showing that first-line intravenous amivantamab (Rybrevant) combined with carboplatin-pemetrexed chemotherapy achieved a median overall survival of 34.3 months in patients with EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer. The results were presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer in Seoul.

The control arm, which received chemotherapy alone, recorded a median OS of 27.9 months (hazard ratio 0.87; 95% CI 0.66–1.14; p=0.307). The difference of more than six months is notable given that 76% of eligible patients in the chemotherapy arm crossed over to second-line amivantamab after disease progression, a factor that typically compresses OS differences between arms in oncology trials. A prespecified crossover-adjusted analysis found a 43% reduction in the risk of death with the combination (HR 0.57; 95% CI 0.39–0.82; nominal p=0.003).

What the survival data mean in context

EGFR exon 20 insertion mutations account for roughly 12% of all EGFR mutations in NSCLC and have historically been harder to address with targeted agents than the more common exon 19 deletions or L858R substitutions. Historical median OS in this population has ranged from approximately 16 to 24 months, with a real-world five-year survival rate of just 8%. The 34.3-month figure reported in PAPILLON is, by the company's account and based on published literature cited in the release, the longest median OS recorded in this setting.

Secondary endpoints strengthened the case. Progression-free survival through second disease progression was extended by more than ten months with the combination versus chemotherapy alone (28.3 vs. 17.5 months; HR 0.59; nominal p<0.0001), and 12% of patients in the amivantamab arm remained on first-line treatment at the clinical cut-off, compared with none in the control arm. Patient-reported outcomes also favoured the combination, with delayed worsening of several lung cancer symptoms.

The safety profile was consistent with earlier PAPILLON reports. The most common treatment-related adverse events, occurring in at least 30% of patients, were paronychia (60%), neutropenia (60%) and rash (58%). No new safety signals emerged with longer follow-up.

Competitive landscape and regulatory positioning

Amivantamab is a bispecific antibody targeting both EGFR and MET, a mechanism J&J says enables it to address activating mutations and resistance pathways simultaneously. The European Commission has approved the drug across multiple NSCLC indications, including first-line use in EGFR exon 20 insertion-positive disease. The PAPILLON primary analysis, which showed a statistically significant 60% improvement in progression-free survival, was published simultaneously in the New England Journal of Medicine and underpinned those approvals.

The exon 20 insertion space remains contested. Mobocertinib, a small-molecule EGFR inhibitor once approved in the US for this indication, was withdrawn by AstraZeneca-partnered Takeda in 2023 after a Phase 3 trial failed to demonstrate superiority over chemotherapy, effectively leaving amivantamab as the dominant targeted option in the first-line setting. J&J is also investigating subcutaneous formulations and prophylactic strategies to improve tolerability, with data from the COPERNICUS and PALOMA-2 studies also presented at WCLC 2026.

Chul Kim, director of thoracic oncology at MedStar Georgetown University Hospital and a named investigator who has served as a consultant to J&J, said patients "are continuing treatment years after they started, which speaks to the durability of this approach." Yusri Elsayed, global head of oncology at J&J, described the OS data as adding to "a growing body of evidence" positioning amivantamab as a backbone therapy across EGFR mutation subtypes.

Near-term attention will focus on whether the crossover-adjusted survival benefit translates into label updates in key markets, and on uptake of the subcutaneous formulation, which could ease the infusion burden that has been a persistent clinical concern with the intravenous regimen.

Sector

Topic

Geography